4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,750,758 | -5.5% | 137,530 | +34.2% | 0.00% | – |
| Q2 2023 | $1,852,320 | -44.1% | 102,508 | -46.9% | 0.00% | – |
| Q1 2023 | $3,315,660 | +92.8% | 192,883 | +149.2% | 0.00% | – |
| Q4 2022 | $1,719,320 | +974.6% | 77,412 | +288.9% | 0.00% | – |
| Q3 2022 | $160,000 | +4.6% | 19,903 | -9.3% | 0.00% | – |
| Q2 2022 | $153,000 | -90.6% | 21,947 | -79.7% | 0.00% | – |
| Q1 2022 | $1,633,000 | -14.9% | 107,980 | +23.5% | 0.00% | – |
| Q4 2021 | $1,918,000 | +462.5% | 87,447 | +592.8% | 0.00% | – |
| Q3 2021 | $341,000 | +28.7% | 12,623 | +14.6% | 0.00% | – |
| Q2 2021 | $265,000 | -10.8% | 11,015 | +60.2% | 0.00% | – |
| Q1 2021 | $297,000 | +14750.0% | 6,877 | +17092.5% | 0.00% | – |
| Q4 2020 | $2,000 | – | 40 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |